KeyCorp Upgrades LivaNova (NASDAQ:LIVN) to “Strong-Buy”

LivaNova (NASDAQ:LIVN) was upgraded by investment analysts at KeyCorp to a “strong-buy” rating in a research note issued to investors on Thursday,Zacks.com reports.

Several other brokerages have also commented on LIVN. Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday. The Goldman Sachs Group set a $55.00 price target on LivaNova and gave the company a “neutral” rating in a research note on Wednesday, October 1st. Mizuho raised their price objective on shares of LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday. Weiss Ratings reiterated a “sell (d+)” rating on shares of LivaNova in a research report on Monday. Finally, Robert W. Baird set a $75.00 target price on shares of LivaNova in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $65.63.

LivaNova Stock Performance

Shares of LIVN opened at $62.82 on Thursday. The company has a current ratio of 1.33, a quick ratio of 1.12 and a debt-to-equity ratio of 0.30. The firm’s fifty day simple moving average is $57.31 and its two-hundred day simple moving average is $52.21. LivaNova has a 12 month low of $32.48 and a 12 month high of $65.57. The stock has a market capitalization of $3.43 billion, a P/E ratio of -15.70 and a beta of 1.02.

Hedge Funds Weigh In On LivaNova

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its position in LivaNova by 13.5% in the 1st quarter. Vanguard Group Inc. now owns 2,666,880 shares of the company’s stock valued at $104,755,000 after purchasing an additional 316,993 shares during the period. Invesco Ltd. lifted its stake in shares of LivaNova by 13.4% in the first quarter. Invesco Ltd. now owns 126,266 shares of the company’s stock valued at $4,960,000 after buying an additional 14,892 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in shares of LivaNova by 4,581.9% during the first quarter. Russell Investments Group Ltd. now owns 70,322 shares of the company’s stock valued at $2,762,000 after buying an additional 68,820 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of LivaNova by 146.1% during the first quarter. Wellington Management Group LLP now owns 472,843 shares of the company’s stock valued at $18,573,000 after buying an additional 280,718 shares during the last quarter. Finally, Hsbc Holdings PLC increased its position in shares of LivaNova by 13.4% during the first quarter. Hsbc Holdings PLC now owns 6,666 shares of the company’s stock worth $258,000 after acquiring an additional 790 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.